H.R. 3932 117th Congress
PASTEUR Act of 2021
- Health
- Sponsor: Rep. Doyle, Michael F. [D-PA-18]
- Congress.gov ↗
Latest action, Aug 2, 2021: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
65 cosponsors
Sponsored by Rep. Doyle, Michael F. [D-PA-18] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
33 D · 32 R
- Democrat
- Republican
- Independent
Referred to: House: Armed Services Committee; House: Energy and Commerce Committee; House: Homeland Security Committee; House: Judiciary Committee; House: Veterans' Affairs Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)
TIBER CREEK GROUP
7 reports
GENENTECH
CAPITOL COUNSEL LLC
7 reports
7 reports
7 reports
6 reports
6 reports
6 reports
MERCK & CO. INC.
AVENUE SOLUTIONS
6 reports
5 reports
CYSTIC FIBROSIS FOUNDATION
THORN RUN PARTNERS
5 reports
5 reports
5 reports
All 25 of 48 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) | TIBER CREEK GROUP | 7 | $420K | Q4 2021 | Q3 2022 | yes |
| GENENTECH | CAPITOL COUNSEL LLC | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| GENENTECH INC | 7 | $14.7M | Q4 2021 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.0M | Q4 2021 | Q3 2022 | yes | |
| INFECTIOUS DISEASES SOCIETY OF AMERICA | 7 | $834K | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $49.3M | Q4 2021 | Q3 2022 | yes | |
| ADVANCED MEDICAL TECHNOLOGY ASSN | 6 | $4.0M | Q4 2021 | Q3 2022 | yes | |
| ELI LILLY AND COMPANY | 6 | $10.3M | Q4 2021 | Q3 2022 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 6 | $292K | Q4 2021 | Q3 2022 | yes | |
| MERCK & CO. INC. | AVENUE SOLUTIONS | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 5 | $16.6M | Q4 2021 | Q3 2022 | yes | |
| CYSTIC FIBROSIS FOUNDATION | 5 | $700K | Q4 2021 | Q3 2022 | yes | |
| CYSTIC FIBROSIS FOUNDATION | THORN RUN PARTNERS | 5 | $0 | Q4 2021 | Q3 2022 | yes |
| HEALTHCARE LEADERSHIP COUNCIL | 5 | $710K | Q3 2021 | Q3 2022 | yes | |
| THERMO FISHER SCIENTIFIC INC | 5 | $3.0M | Q4 2021 | Q3 2022 | yes | |
| ANTIMICROBIAL INNOVATION ALLIANCE | FORBES-TATE | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| IGM BIOSCIENCES, INC. | 4 | $660K | Q1 2022 | Q3 2022 | yes | |
| INFECTIOUS DISEASES SOCIETY OF AMERICA | ARENTFOX SCHIFF LLP | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| MERCK & CO INC | 4 | $8.3M | Q1 2022 | Q3 2022 | yes | |
| PFIZER INC. | 4 | $11.4M | Q1 2022 | Q3 2022 | yes | |
| THE PEW CHARITABLE TRUSTS | 4 | $840K | Q1 2022 | Q3 2022 | yes | |
| THERMO FISHER SCIENTIFIC INC | BLUEBIRD STRATEGIES | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| TRUST FOR AMERICA'S HEALTH | 4 | $174K | Q1 2022 | Q3 2022 | yes | |
| GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP, NORTH AMERICA (GARDP NA) | VENABLE LLP | 3 | $0 | Q4 2022 | Q3 2022 | yes |
| THE PEGGY LILLIS FOUNDATION | BLUEBIRD STRATEGIES | 3 | $0 | Q1 2022 | Q3 2022 | yes |